FatCool schreef op 10 april 2020 09:11:
Endless, kijk uit met Gilead.
Covid-19 gaat echt niet lukken en hun HIV business is op drijfzand gebouwd (ze hebben geluk dat CytoDyn een slak is met hun BLA). Zonder de deal met Galapagos zou het een "strong sell" zijn. Nu hooguit een aanhouden.
fc
Gilead Generates Street Skepticism Ahead of Covid-19 Results7 April 2020 13:34 CEST Updated on 7 April 2020 16:03 CEST
Results from a study of Gilead Sciences Inc.’s experimental Covid-19 medicine are top-of-mind for Wall Street as cases surpass 1.35 million and deaths approach 76,000.
With a potential vaccine more than a year away, Gilead’s antiviral remdesivir offers one of the nearest-term hopes for a treatment in the pandemic that’s sweeping across the globe and putting many countries, including most of the U.S., on lockdown. Results from late-stage studies out of China are expected this month with results from U.S. trials following in May.
After the company’s valuation surged more than $20 billion from late January to early March, some Wall Street analysts are cautioning there may not be much more room for shares to gain. The stock has traded sideways since hitting a two-year high on March 6.
“We see a highly negatively skewed risk/reward,” Barclays analysts led by Carter Gould warned ahead of the April data. They rate Gilead underweight.
----
Even the bulls have doubts about the upcoming data. Evercore ISI analyst Umer Raffat, who has an outperform rating on the stock, said he expects the study in severely ill patients “may underwhelm,” though he said remdesivir could help those who received the drug early enough in their course of treatment. Optimism that Gilead has started ramping up production because it knows the medicine works is also unfounded, he said, noting management confirmed they haven’t seen results from the Chinese trials.
www.bloomberg.com/news/articles/2020-...